Table 4 Overview of the trials currently recruiting chondrosarcoma patients, showing the clinicaltrials.gov number, title of the study and the phase
Clinicaltrials.gov number | Title | Phase |
|---|---|---|
NCT01522820 | Vaccine therapy with or without sirolimus in treating patients with NY-ESO-1 expressing solid tumors | I |
NCT01643278 | Dasatinib and ipilimumab in treating patients with gastrointestinal stromal tumors or other sarcomas that cannot be removed by surgery or are metastatic | I |
NCT01154452 | Vismodegib and gamma-secretase/notch signalling pathway inhibitor RO4929097 in treating patients with advanced or metastatic sarcoma | IB/II |
NCT01330966 | Study of pazopanib in the treatment of surgically unresectable or metastatic chondrosarcoma | II |
NCT00928525 | Imatinib in patients with desmoid tumor and chondrosarcoma | II |
NCT01653028 | Alisertib in treating patients with advanced or metastatic sarcoma | II |
Not yet assigned | A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma. | II |